论文部分内容阅读
目的：探讨抗胃癌单克隆抗体ＭＧ７、ＭＧｄ１在卵巢粘液上皮肿瘤（ＯＭＥＴ）组织中的表达与临床资料和患者预后的关系。方法：应用免疫组化ＳＰ法检测９３份ＯＭＥＴ组织中ＭＧ７、ＭＧｄ１的表达，并对１４ａ经手术切除、病理学检查证实的ＯＭＥＴ患者的临床资料进行患者预后分析。结果：ＭＧ７、ＭＧｄ１定位于ＯＭＥＴ细胞膜及附近的胞浆，ＭＧ７在良性、交界性、恶性组表达率分别为０、８０．６５％、１００％，ＭＧｄ１分别为２６．４７％、９６．７７％、１００％。３组间差异有显著性（Ｐ＜０．０５）。恶性组ＭＧ７过度表达率比ＭＧｄ１者高１４．２８％。将本组ＯＭＥＴ的临床资料、ＭＧ７和ＭＧｄ１染色结果分别经ＣＯＸ风险模型分析，发现期别、肿瘤直径和ＭＧ７染色指标是影响患者预后的主要因素。ＯＭＥＴＭＧ７表达（—）、（＋）、（）和（）组的患者５ａ生存率分别为１００％、７２．３７％、２７．９％和１３．１３％，ＭＧｄ１分别为（—）１００％、（＋）７５．０５％、（）３１．４７％、（）０．００％。结论：卵巢癌与胃癌组织间存在共同抗原性，具有同源性。ＭＧ７、ＭＧｄ１对ＯＭＥＴ的诊断有一定的特异性和敏感性，与临床病理分级、分类及预后有关，为ＯＭＥＴ的?
Objective: To investigate the relationship between the expression of anti-gastric cancer monoclonal antibody MG7 and MGd1 in ovarian mucoepithelial neoplasm (OMET) and their clinical data and prognosis. Methods: The expressions of MG7 and MGd1 in 93 OMET tissues were detected by immunohistochemical SP method. The prognosis of patients with OMET proved by pathological examination after 14a surgical resection was analyzed. Results: The expressions of MG7 and MGd1 were localized in the cytoplasm of OMET and nearby cells. The expression rates of MG7 in benign, borderline and malignant groups were 0, 80.65% and 100%, respectively. MGd1 was 26.47% and 96.77% , 100%. The difference between the three groups was significant (P <0.05). The over-expression rate of MG7 in malignant group was 14.28% higher than that in MGd1. The clinical data of this group OMET, MG7 and MGd1 staining results were analyzed by COX risk model and found that the stage, tumor diameter and MG7 staining index is the main factor affecting the prognosis of patients. The survival rates of patients with OMETMG7 expression (-), (+), () and () were 100%, 72.37%, 27.9% and 13.13%, respectively %, (+) 75.05%, () 31.47%, () 0.00%. Conclusion: Ovarian cancer and gastric cancer have common antigenicity and homology. MG7, MGd1 OMET diagnosis of a certain specificity and sensitivity, and clinicopathological grade, classification and prognosis, as OMET?